Research never stops

High-content screening

Evotec specialises in the development and implementation of high-content based assays for high-throughput screening and compound validation to probe the pathophysiological environment. High-content screening (“HCS”) is routinely used throughout the hit identification cascade from target validation to mechanistic studies. The assays developed at Evotec encompass both a target centric as well as phenotypic approach with emphasis on tissue samples, stem cell derived or primary cells from appropriate hosts. This approach is a core part of Evotec’s efforts to identify novel targets and drugs with disease-modifying potential.

Evotec’s HCS expertise is built around the OPERA® platform where an essential understanding of the mechanics and image analysis tools, gathered over a period of more than 15 years in the development of the platform, flows into the hit identification process. Additional platforms include the Operetta® and ArrayScan™ to fulfill different requirements in resolution and throughput. The platform is completed with a powerful data management system and powerful data analysis tools including multifactorial analysis. Based on this expertise, Evotec has performed many high-throughput screens of up to 400,000 compounds and developed over 30 assays to study mode of action of compounds and targets in a multitude of cellular backgrounds.

For more detailed information, please click on this link or contact us at info@evotec.com.

High-content screening